JNPMEDI, led by CEO Kwunho Jeong, announced its entry into the 'Innovative Biotech and Medical Device Investment Support Program' on April 24th, aimed at supplying new growth momentum to the domestic pharmaceutical and biotech markets.
The 'Innovative Biotech and Medical Device Investment Support Program' is a business model where JNPMEDI leverages its Maven Clinical Cloud solution capabilities and investment network to match pharmaceutical and medical device companies with investors. JNPMEDI will directly execute investments and act as a pivotal link to connect with large-scale investment firms.
For biotech companies, JNPMEDI will provide end-to-end solutions from funding opportunities to clinical trials, commercialization, and licensing agreements. For investors, it will support a transparent assessment of business progress, including the status of clinical trials of connected companies.
JNPMEDI has identified that many small to medium-sized pharmaceutical and medical device companies are encountering funding challenges despite their competitive advantages. Meanwhile, numerous investment firms are actively seeking attractive opportunities in the pharmaceutical and biotech sectors. However, these sectors face difficulties in evaluating research outcomes and clinical progress. In response, JNPMEDI has initiated plans for new business ventures to address these challenges.
Participating companies will be able to establish close connections with key domestic and international investment firms. Currently, JNPMEDI holds an extensive global investment network including major institutional investors such as Singapore's Temasek through Pavilion Capital, Murex Partners, Kakao Ventures, AJU IB Investment, and Gentium Partners, among others.
All domestic and international companies planning pharmaceutical and medical device development are eligible to participate in JNPMEDI's Innovative Biotech and Medical Device Investment Support Program. Utilizing JNPMEDI's Maven Clinical Cloud solution, companies can advance their medical business commercialization, apply for selection, and join the process.
Kwunho Jeong, CEO of JNPMEDI, stated, "At a stage where companies are growing into digital medical hubs centered around technological prowess, we conceived a new business to expand platform capabilities and leave a precedent for contributing to industry development and activation."
JNPMEDI, led by CEO Kwunho Jeong, announced its entry into the 'Innovative Biotech and Medical Device Investment Support Program' on April 24th, aimed at supplying new growth momentum to the domestic pharmaceutical and biotech markets.
The 'Innovative Biotech and Medical Device Investment Support Program' is a business model where JNPMEDI leverages its Maven Clinical Cloud solution capabilities and investment network to match pharmaceutical and medical device companies with investors. JNPMEDI will directly execute investments and act as a pivotal link to connect with large-scale investment firms.
For biotech companies, JNPMEDI will provide end-to-end solutions from funding opportunities to clinical trials, commercialization, and licensing agreements. For investors, it will support a transparent assessment of business progress, including the status of clinical trials of connected companies.
JNPMEDI has identified that many small to medium-sized pharmaceutical and medical device companies are encountering funding challenges despite their competitive advantages. Meanwhile, numerous investment firms are actively seeking attractive opportunities in the pharmaceutical and biotech sectors. However, these sectors face difficulties in evaluating research outcomes and clinical progress. In response, JNPMEDI has initiated plans for new business ventures to address these challenges.
Participating companies will be able to establish close connections with key domestic and international investment firms. Currently, JNPMEDI holds an extensive global investment network including major institutional investors such as Singapore's Temasek through Pavilion Capital, Murex Partners, Kakao Ventures, AJU IB Investment, and Gentium Partners, among others.
All domestic and international companies planning pharmaceutical and medical device development are eligible to participate in JNPMEDI's Innovative Biotech and Medical Device Investment Support Program. Utilizing JNPMEDI's Maven Clinical Cloud solution, companies can advance their medical business commercialization, apply for selection, and join the process.
Kwunho Jeong, CEO of JNPMEDI, stated, "At a stage where companies are growing into digital medical hubs centered around technological prowess, we conceived a new business to expand platform capabilities and leave a precedent for contributing to industry development and activation."